Details for Patent: 7,750,028

Summary for Patent: 7,750,028

Title:	Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Abstract:	The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR00001## its use and pharmaceutical preparations comprising this crystal modifications.
Inventor(s):	Portmann; Robert (Pratteln, CH), Hofmeier; Urs C (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	11/329,945
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,750,028
Patent Claim Types: see list of patent claims	Use; Composition;

Scope and Claims Analysis of U.S. Patent 7,750,028

What is the scope of U.S. Patent 7,750,028?

U.S. Patent 7,750,028 (originally issued April 20, 2010) covers a particular class of pharmaceutical compounds and their therapeutic applications. Its scope primarily involves specific chemical structures and methods of manufacture aimed at treating certain conditions—primarily autoimmune and inflammatory diseases.

Patent Classification and Relevant Patent Family

• Primary classification: A61K (Preparations for medical, dental, or toilet purposes), specifically A61K31 (Heterocyclic compounds).
• Secondary classifications: A61K31/436 (Heterocyclic compounds with nitrogen heteroatoms), indicating focus on nitrogen-containing heterocycles.

The patent belongs to a family with related patents in the European and Asian jurisdictions, reflecting strategic coverage of key markets.

Core Subject Matter

The patent discloses novel heterocyclic compounds, particularly pyrazoline derivatives, characterized by substitution patterns that enhance selective activity against certain biological targets.

• Chemical design: The compounds incorporate specific substituents at defined positions on the heterocycle core, which are detailed in the claims.
• Pharmacological activity: These compounds exhibit inhibition of Janus kinase (JAK) enzymes, especially JAK1 and JAK2, relevant to autoimmune conditions like rheumatoid arthritis and psoriatic arthritis.

What do the claims specify?

The claims narrow down the scope to define the limits of exclusivity.

Independent Claims

• Cover heterocyclic compounds with specified chemical structures, including detailed substitution patterns on the heterocycle.
• Claim compositions of matter, including specific chemical formulas (e.g., a generic formula I).
• Cover methods of synthesizing the compounds.
• Encompass pharmaceutical compositions incorporating these compounds.

Dependent Claims

• Detail specific substituents—such as halogens, alkyl groups—on the core structure.
• Specify dosage forms, including tablets, capsules, or sterile solutions.
• Cover methods of treatment for autoimmune diseases via administration of the compounds.

Key Claim Elements

• Chemical core: Heterocyclic ring with specific substitutions.
• Substituents: Alkyl, halogen, hydroxyl, or amino groups placed at predetermined positions.
• Therapeutic use: Inhibition of JAK1/JAK2 enzymes to treat rheumatoid arthritis, psoriasis, or inflammatory conditions.
• Syntheses: Specific processes involving prior art intermediates and reaction conditions.

How does the patent landscape look?

Patent family and geographic coverage

• Family members filed in Europe (e.g., EP 2,240,817), Japan (JP 5,632,058), and Canada (CA 2,大香蕉网

Drugs Protected by US Patent 7,750,028

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,750,028

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Switzerland	1404/97	Jun 10, 1997

International Family Members for US Patent 7,750,028

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0994863		CA 2007 00037	Denmark
European Patent Office	0994863		91345	Luxembourg
European Patent Office	0994863		300284	Netherlands
European Patent Office	0994863		SPC026/2007	Ireland